Tidal Investments LLC Boosts Stake in Kenvue Inc. (NYSE:KVUE)

Tidal Investments LLC raised its holdings in Kenvue Inc. (NYSE:KVUE) by 47.5% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 131,764 shares of the company’s stock after purchasing an additional 42,418 shares during the quarter. Tidal Investments LLC’s holdings in Kenvue were worth $2,828,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. California State Teachers Retirement System grew its stake in shares of Kenvue by 1.2% in the first quarter. California State Teachers Retirement System now owns 2,854,690 shares of the company’s stock valued at $61,262,000 after buying an additional 33,494 shares in the last quarter. Ancora Advisors LLC grew its stake in shares of Kenvue by 4.4% in the first quarter. Ancora Advisors LLC now owns 484,360 shares of the company’s stock valued at $10,394,000 after buying an additional 20,406 shares in the last quarter. Dynasty Wealth Management LLC acquired a new stake in shares of Kenvue in the first quarter valued at $914,000. Janus Henderson Group PLC grew its stake in shares of Kenvue by 53.7% in the first quarter. Janus Henderson Group PLC now owns 165,162 shares of the company’s stock valued at $3,541,000 after buying an additional 57,679 shares in the last quarter. Finally, Kinloch Capital LLC grew its stake in shares of Kenvue by 24.4% in the first quarter. Kinloch Capital LLC now owns 81,042 shares of the company’s stock valued at $1,739,000 after buying an additional 15,894 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Stock Performance

Shares of Kenvue stock traded down $0.01 on Thursday, hitting $18.48. The stock had a trading volume of 3,418,492 shares, compared to its average volume of 19,004,184. Kenvue Inc. has a 52-week low of $17.67 and a 52-week high of $24.43. The company has a current ratio of 0.99, a quick ratio of 0.68 and a debt-to-equity ratio of 0.66. The stock has a market cap of $35.39 billion, a price-to-earnings ratio of 23.73, a P/E/G ratio of 2.08 and a beta of 1.40. The company’s 50 day moving average price is $18.52 and its 200 day moving average price is $19.48.

Kenvue (NYSE:KVUE) last posted its earnings results on Tuesday, May 7th. The company reported $0.28 earnings per share for the quarter, beating the consensus estimate of $0.25 by $0.03. Kenvue had a return on equity of 21.06% and a net margin of 9.63%. The business had revenue of $2.89 billion during the quarter, compared to the consensus estimate of $3.79 billion. Kenvue’s revenue was down 24.9% compared to the same quarter last year. On average, research analysts anticipate that Kenvue Inc. will post 1.13 EPS for the current year.

Kenvue Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, August 28th. Stockholders of record on Wednesday, August 14th will be issued a $0.205 dividend. This is an increase from Kenvue’s previous quarterly dividend of $0.20. This represents a $0.82 annualized dividend and a dividend yield of 4.44%. The ex-dividend date of this dividend is Wednesday, August 14th. Kenvue’s payout ratio is presently 105.13%.

Analyst Ratings Changes

Several research firms recently commented on KVUE. Citigroup lowered their target price on Kenvue from $21.00 to $20.00 and set a “neutral” rating for the company in a research note on Wednesday, July 10th. William Blair began coverage on Kenvue in a research note on Wednesday, April 3rd. They set a “market perform” rating for the company. Deutsche Bank Aktiengesellschaft lowered their target price on Kenvue from $24.00 to $23.00 and set a “buy” rating for the company in a research note on Thursday, July 25th. JPMorgan Chase & Co. lowered their target price on Kenvue from $23.00 to $22.00 and set an “overweight” rating for the company in a research note on Monday, July 22nd. Finally, Sanford C. Bernstein began coverage on Kenvue in a research note on Thursday, April 11th. They set an “underperform” rating and a $18.00 target price for the company. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $22.45.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.